Articles by Erin Trish in JoVE
Other articles by Erin Trish on PubMed
调整风险选择的国家健康保险交易所将是极其重要和可行的但不是容易。 Health Affairs (Project Hope). Feb, 2012 | Pubmed ID: 22323160 负担得起照料法 》 要求建立的国家级健康保险交易所。可行性和这种交流的成功将需要有效的风险调整战略，弥补中注册的健康状况差异跨健康计划。这篇文章描述了为什么可负担得起的护理行为可能导致计划的有利或不利的风险选择。它审查规定法 》 和最近拟议的规例，目的是减轻风险选择的问题。我们执行一个模拟，以表明在法中的地价分级限制下, 大优惠政策吸引更健康注册的保险公司将可能持续造成大量超额支付与非常健康注册计划及短付工资计划与病得很重的成员中。我们得出结论基于病人的诊断，如风险调整将到位从 2014 年，将产量支付给保险公司，将比单从年龄调整和法允许其他评级会发生什么更准确。我们还描述了实施风险调整的更多的挑战。
Specialty Drug Spending Trends Among Medicare and Medicare Advantage Enrollees, 2007-11 Health Affairs (Project Hope). Nov, 2014 | Pubmed ID: 25367998 Specialty pharmaceuticals include most injectable and biologic agents used to treat complex conditions such as rheumatoid arthritis, multiple sclerosis, and cancer. We analyzed trends in specialty drug spending among Medicare beneficiaries ages sixty-five and older using 2007-11 pharmacy claims data from a 20 percent sample of Medicare beneficiaries. Annual specialty drug spending per beneficiary who used specialty drugs increased considerably during the study period, from $2,641 to $8,976. However, specialty drugs accounted for only 6.7 percent of total drug spending per beneficiary in 2007 and 9.1 percent in 2011. Moreover, in 2011 cost-sharing reductions under the Affordable Care Act significantly reduced specialty drug users' out-of-pocket burden, which decreased 26 percent from 2010. Oral cancer agents accounted for a significant proportion of the increase in specialty drug spending among the study population. This suggests that the migration of specialty drug coverage from Medicare's Part B medical benefit to the Part D pharmacy benefit because of new treatment options may play an important role in specialty pharmacy trends. This shift is likely to continue as pharmaceutical innovations enable more specialty therapeutics to be self-administered and to be covered under the pharmacy instead of the medical benefit.